Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV

Status Completed

Clinical Trial Summary

This is a Post-Market Evaluation of the Zephyr Valve 5.5-LP EBV to assess Treated Lobar Volume Reduction (TLVR), changes in lung function and the safety profile of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV.

Clinical Trial Description

This is a multi-center, single-arm, prospective, observational study. Approximately 70 study participants undergoing Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP EBV will be enrolled and followed out to 3 months. Assessments will be conducted at 45 days and 3 months. The evaluation will be conducted at up to 6 sites. Patients prescribed Zephyr Valve treatment for their emphysema will be consented and will be enrolled only after: 1) determination of little to no collateral ventilation between target and ipsilateral lobes and 2) implantation of at least one Zephyr Valve 5.5-LP EBV. Baseline data will be collected retrospectively after enrollment of a patient in the Post-Market Evaluation. Performance and safety of the Zephyr Valve treatment with the use of at least one Zephyr Valve 5.5-LP will be evaluated post-treatment based on data collected until 3 months after the treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04161235
Study type	Observational [Patient Registry]
Source	Pulmonx Corporation
Contact
Status	Completed
Phase
Start date	February 5, 2020
Completion date	December 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00995852` - Unilateral Versus Bilateral Endoscopic Lung Volume Reduction A Comparative Case Study	Phase 2/Phase 3
Completed	`NCT01860898` - A Phase I Study of iPS Cell Generation From Patients With COPD	N/A
Completed	`NCT00123422` - Innovation in Pulmonary Rehabilitation	N/A
Recruiting	`NCT02879331` - Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils	N/A
Completed	`NCT01507415` - Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD?	N/A
Completed	`NCT01051258` - AeriSeal System for Lung Volume Reduction	Phase 1/Phase 2
Completed	`NCT00680056` - Add-on Effects of Tiotropium Over Formoterol in Exercise Tolerance on Chronic Obstructive Pulmonary Disease Patients	Phase 4
Completed	`NCT01872624` - Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema	N/A
Completed	`NCT01110252` - Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease	N/A
Completed	`NCT00517998` - Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study	Phase 1
Terminated	`NCT00205920` - Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation	Phase 2
Withdrawn	`NCT01849159` - Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema	Phase 1/Phase 2
Completed	`NCT01869205` - The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients	Phase 3
Terminated	`NCT01320566` - A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema	Phase 2/Phase 3
Completed	`NCT00683722` - PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)	Phase 2
Active, not recruiting	`NCT04465461` - Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion	N/A
Completed	`NCT04012359` - Description of Bullous Emphysema Using Lung Ultrasound and Comparison to the Characteristics of Pneumothorax
Recruiting	`NCT04918706` - Allogeneic MSC Treatment for Pulmonary Emphysema	Phase 2
Terminated	`NCT01449292` - Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)	Phase 3
Completed	`NCT00347659` - US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study	Phase 1